@AdamJanuszewski

Thoracic Medical Oncologist @BartsHospital, PhD in genomic medicine @Imperialcollege, Representative @ACPUK & @BTOGorg, @FMLM_UK clinical Fellow β€˜18

 London, England
Joined March 2012
  • Tweets834
  • Following1.1K
  • Followers1.1K
231Media
🚨 #ESMO26 Another promising ADC in 2L EGFRm NSCLC! Ph3 HER3 ADC ruzaltatug rezetecan vs chemo: πŸ“ˆ PFS 8.3 vs 5.4m (HR 0.47) πŸ“ˆ ORR 60% vs 34% πŸ“ˆ OS HR 0.70 (immature) ⚠️ ILD 2.4% Competitive ADC landscape! More mature OS & global data needed.
33
🚨 #ESMO26 Iza-bren πŸ‡¨πŸ‡³ Ph3 in EGFRm NSCLC post-TKI: πŸ“ˆ PFS 11.1 vs 5.7m (HR 0.40) πŸ“ˆ OS HR 0.66 (immature) βœ… ILD 0.9% A top contender among 2L ADCs? πŸ‡¬πŸ‡§ Excited to open global Ph3 IZABRIGHT-Lung01 at Barts in the next 2 weeks!
42
🚨 #ESMO26 Another Ph3 study reinforcing MET amp as a key target in EGFRm NSCLC! Dalmelitinib + aumolertinib vs chemo post-EGFR TKI: πŸ“ˆ PFS 6.2 vs 4.4m (HR 0.60) πŸ”¬ Reinforces importance of rebiopsy at progression, MET-amp accounts for ~10–15% (definition-dependent).
4
191
🚨 #ESMO26 SANOVO Ph3 πŸ‡¨πŸ‡³ (China-only) Impressive 1L savolitinib + osimertinib in EGFRm/MET-OE NSCLC: πŸ“ˆ PFS 24.9 vs 13.8m (HR 0.56) πŸ“ˆ OS 44.5 vs 34.9m (HR 0.48) MET is a key target! ❓Target MET in 1L or 2L? Amivantimab already targets MET. Efficacy similar. Tox will be key
51
🚨 ?another practice-changing #ESMO2026 result! Phase III #SAFFRON establishes osi + savo as a NEW SOC for EGFRm/MET+ #NSCLC progressing on osimertinib. πŸ“ˆ PFS: 7.6 vs 5.4m (HR 0.55) πŸ“ˆ significant OS: 17.8 vs 12.9m (HR 0.68) πŸ”¬ Importance of RE-BIOPSY at progression
1
127
🚨 Practice-changing KRAS G12C NSCLC #ESMO26 Divarasib may be the most potent inhibitor yet πŸ“ˆ PFS: 9.8 vs 5.7m (HR 0.58) πŸ“ˆ OS: 17.7 vs 12.0m (HR 0.56) 🎯 ORR: 58% vs 32% Rapid πŸ‡¬πŸ‡§ reimbursement needed given challenges with sotorasib. πŸ”¬ KRASCENDO-2 is OPEN at Barts!
2
3
242
🫁 #ESMO2026 OptiTROP-Lung04: Final OS analysis of sac-TMT vs chemotherapy in EGFRm NSCLC after EGFR-TKI progression. πŸ‡¨πŸ‡³ Chinese-only phase III (n=376) πŸ“ˆ OS: 25.9 vs 17.4m (HR 0.69) Impressive OS benefit. Global data will be important 2nd line EGFR setting v. complex
1
2
181
🫁 #ESMO2026 OptiTROP-Lung06: sac-TMT + pembro vs chemo + pembro in PD-L1-negative NSCLC in china. High never smoker (30%) and male (60%) popn. Promising PFS: 15.0 vs 5.7m (HR 0.49). OS immature. Global data awaited Sac-TMT is also in clinical trials at @NHSBartsHealth
1
1
136
🫁 PERSEE phase III: Pembro + chemo vs pembro alone in PD-L1 β‰₯50% NSCLC. πŸ“ˆ PFS: 16.1 vs 6.9m (HR 0.56) OS: HR 0.77 (95% CI 0.57–1.05) 29.9vs50 mo ⚠️ Grade β‰₯3 TRAEs: 54% vs 19% Better disease control, numerical better OS. Patient selection key - practice informing #ESMO2026
2
120
πŸ‡¬πŸ‡§ UK-led SARON trial at #ESMO2026: 140 patients across 22 centres. Adding RT to systemic therapy in oligometastatic NSCLC improved PFS (13.9 vs 8.9 months) and local control, but not OS (HR 0.99). Important UK academic research informing clinical practice. #LungCancer #ESMO26
2
8
336
Dr Adam Januszewski retweeted
Rami Manochakian MD, FASCO
@RManochakianOct 24
🚨πŸ”₯@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 the long-awaited #PracticeChanging results of: ⭐️#DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab. Study showed: ‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit. βœ…#mOS: 21.1 vs 12.7 months (HR 0.42) βœ…12-month OS: 79.4% vs 53.3% βœ…#mPFS: 7.4 vs 1.9 months (HR 0.34) ⚠️ Grade β‰₯3 #AEs: 46.8% vs 40.6% * In Tarlatamab arm: #CRS: 49.6% (Grade β‰₯3: 0.4%) #ICANS: 1.1% (Grade β‰₯3: 0%) πŸ‘‡πŸ» nejm.org/doi/full/10.1056/NE…
3
44
4
84
5,831
🚨 PRACTICE-CHANGING in #SCLC! DeLLphi-305: tarlatamab + durvalumab maintenance βœ… 58% ↓ risk of death βœ… Median OS 21.1 vs 12.7 months βœ… 66% ↓ progression/death A huge advance for historically underserved patients with poor outcomes. πŸ‡¬πŸ‡§ Let’s expedite UK approval & NHS access
9
397
πŸ‡¬πŸ‡§ Brilliant to see @tompowles1 AGAIN on the podium, leading the way in bladder cancer! 🚨 Phase III VOLGA: βœ… 49% ↓ EFS events/death βœ… 42% ↓ risk of death βœ… 45% pCR vs 10% Fantastic UK & @NHSBartsHealth representation! πŸ‘ #BladderCancer #VOLGA #ESMO2026
2
1
200
🚨 Landmark Phase III cancer vaccine results! Personalised mRNA vaccine + pembrolizumab in melanoma: ⬇️ 42% risk of recurrence/death ⬇️ 38% risk of distant metastasis/death 🫁 Trials also recruiting in lung cancer, including early-stage disease at Barts! #ESMO26
2
2
3
334
Dr Adam Januszewski retweeted
Rami Manochakian MD, FASCO
@RManochakianSep 8
🚨πŸ”₯‼️@OncoAlert Hot off the press. #BigNews #PressRelease by @Amgen ⭐️ #DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with Chemo + Durvalumab. Showed: βœ…Statistically Significant & Clinically meaningful ⬆️#OverallSurvival (#OS) Benefit. πŸ‘‡πŸ» tinyurl.com/ytxbe2xf
2
26
6
73
16,653
Dr Adam Januszewski retweeted
Genentech
@genentechJul 2
#Breaking: New positive Phase III results demonstrate superiority of an investigational molecule over standard-of-care KRAS G12C inhibitors in the first global head-to-head study in KRAS G12C-mutant non-small cell lung cancer: gene.com/media/press-release…
1
5
1
12
6,644
Impressive data with mRNA personalised vaccine seen here in patients with melanoma. Trials in lung cancer open and recruiting (open at SBH) and we look forward to see outcome data! #ASCO26
Eric Topol
@EricTopolJun 1
Another major advance vs cancer! @ASCO #ASCO26 Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda) ascopubs.org/doi/10.1200/JCO…
158
Dr Adam Januszewski retweeted
Stephen V Liu, MD
@StephenVLiuJun 1
#ASCO26 With neoadjuvant lorlatinib, pCR 47% and MPR 81%. Amazing. RR 84% and 1y EFS 97%. Down staging of nodes in 90%. Very reassuring and consistency safety results. Phenomenal clinical results.
2
27
3
55
13,316
Great to see @AlfredSo12 presenting UK-wide data on behalf of @onctrainees @ASCO on time of day data in patients with NSCLC receiving IO. #ASCO2026
1
2
4
365
Dr Adam Januszewski retweeted
NEJM
@NEJMMay 31
Presented at #ASCO26: Among patients with π˜™π˜Œπ˜› fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels. Full phase 3 LIBRETTO-432 trial results: nej.md/3Q3QcIo @ASCO
Graph depicting survival rates over time for patients using selpercatinib versus a placebo in early-stage RET fusion-positive non-small-cell lung cancer. The x-axis shows months since randomization, and the y-axis represents the percentage of patients. The logo for the New England Journal of Medicine is present.

ALT Graph depicting survival rates over time for patients using selpercatinib versus a placebo in early-stage RET fusion-positive non-small-cell lung cancer. The x-axis shows months since randomization, and the y-axis represents the percentage of patients. The logo for the New England Journal of Medicine is present.

71
2
232
26,046
Load more